AMBRX
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.
AMBRX
Industry:
Biopharma Biotechnology Health Care Life Science Therapeutics
Founded:
2003-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.ambrx.com
Total Employee:
101+
Status:
Active
Contact:
(858)875-2479
Email Addresses:
[email protected]
Total Funding:
347.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Google Tag Manager WordPress Domain Not Resolving Wordpress Plugins Sitelinks Search Box
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cognition Therapeutics
Cognition Therapeutics develops new therapeutics to treat patients suffering from Alzheimer’s disease and other neurodegenerative disorders.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Suvretta Capital Management
Suvretta Capital Management investment in Private Equity Round - Ambrx
Cormorant Asset Management
Cormorant Asset Management investment in Private Equity Round - Ambrx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Private Equity Round - Ambrx
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Private Equity Round - Ambrx
Invus
Invus investment in Private Equity Round - Ambrx
BlackRock
BlackRock investment in Private Equity Round - Ambrx
Adage Capital Management
Adage Capital Management investment in Private Equity Round - Ambrx
HOPU Investment Management Company
HOPU Investment Management Company investment in Venture Round - Ambrx
Northeast Securities
Northeast Securities investment in Venture Round - Ambrx
Everbright
Everbright investment in Venture Round - Ambrx
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-16 | Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian |
| 2021-06-30 | Ambrx Appoints Sonja Nelson as Chief Financial Officer |
Official Site Inspections
http://www.ambrx.com Semrush global rank: 2.71 M Semrush visits lastest month: 6.08 K
Unable to get host informations!!!
More informations about "Ambrx"
Ambrx - Crunchbase Company Profile & Funding
Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation.See details»
About | Ambrx
Our internal pipeline is focused on creating next generation antibody drug conjugates (ADCs) for a variety of cancer indications, including our lead product candidate ARX517, a prostate-specific membrane antigen (PSMA) targeting …See details»
Ambrx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Ambrx, Inc. with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 95 news, and 35 literature, Disease Domain:Neoplasms, Hemic and Lymphatic Diseases, …See details»
Ambrx - Ambrx Biopharma Inc. Announces Strategic …
Oct 18, 2022 Ambrx will leverage clinical data from its partners who are progressing the two assets to inform Ambrx-sponsored clinical trials. Anticipated Near Term Pipeline Milestones …See details»
Investor Relations - Ambrx
Nov 14, 2023 Corporate Overview Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision …See details»
Ambrx - LinkedIn
Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and ...See details»
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation …
Jan 8, 2024 Additional Information and Where to Find It This press release may be deemed to be solicitation material in respect of the proposed acquisition of Ambrx by Johnson & Johnson. …See details»
Ambrx Biopharma Inc. - AnnualReports.com
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune …See details»
Ambrx - Funding, Financials, Valuation & Investors
Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation.See details»
Johnson & Johnson Completes Acquisition of Ambrx
NEW BRUNSWICK, NJ (March 7, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage …See details»
Ambrx Company Profile - Office Locations, Competitors, Revenue ...
Mar 7, 2024 Ambrx has 1 employees at their 1 location and $7.4 m in annual revenue in FY 2022. See insights on Ambrx including office locations, competitors, revenue, financials, …See details»
Ambrx - Contacts, Employees, Board Members, Advisors & Alumni
Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation.See details»
Corporate Presentation - ambrx.com
These forward-looking statements are based on information available to, and expectations of, Ambrx as of the date of this presentation. Ambrx disclaims any obligation to update these …See details»
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation …
Jan 8, 2024 Johnson & Johnson and Ambrx and their respective directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be …See details»
Johnson & Johnson Completes Acquisition of Ambrx | Johnson
Mar 7, 2024 Acquisition strengthens Johnson Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted …See details»
Ambrx - Financials - SEC Filings
News Events & Presentations Quarterly Reports Annual Reports SEC Filings End of Day Stock QuoteSee details»
Ambrx Announces Formation and Members of Scientific Advisory …
Jun 11, 2021 SAN DIEGO– (BUSINESS WIRE)–Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop …See details»
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation …
Jan 8, 2024 Johnson& Johnson announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx, a clinical-stage biopharmaceutical company with a …See details»
Ambrx, Inc. (Ambrx, Inc.) - 药物管线_专利_临床试验_投融营收_最新 …
了解Ambrx, Inc. (Ambrx, Inc.)公司的药物管线，治疗领域，技术平台，以及它的7项临床试验, 285篇新闻和24篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，免疫系统疾病，内分泌与代谢 …See details»